Overview

  • Product name
    Anti-HMW Kininogen antibody (Biotin)
    See all HMW Kininogen primary antibodies
  • Description
    Rabbit polyclonal to HMW Kininogen (Biotin)
  • Conjugation
    Biotin
  • Tested applications
    Suitable for: WB, IP, ELISA, RIAmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    HMW Kininogen purified from human plasma

Properties

Applications

Our Abpromise guarantee covers the use of ab79654 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/20. Predicted molecular weight: 72 kDa.
IP Use at an assay dependent dilution.
ELISA Use a concentration of 3 - 8 µg/ml.
RIA Use a concentration of 3 - 8 µg/ml.

Target

  • Function
    (1) Kininogens are inhibitors of thiol proteases; (2) HMW-kininogen plays an important role in blood coagulation by helping to position optimally prekallikrein and factor XI next to factor XII; (3) HMW-kininogen inhibits the thrombin- and plasmin-induced aggregation of thrombocytes; (4) the active peptide bradykinin that is released from HMW-kininogen shows a variety of physiological effects: (4A) influence in smooth muscle contraction, (4B) induction of hypotension, (4C) natriuresis and diuresis, (4D) decrease in blood glucose level, (4E) it is a mediator of inflammation and causes (4E1) increase in vascular permeability, (4E2) stimulation of nociceptors (4E3) release of other mediators of inflammation (e.g. prostaglandins), (4F) it has a cardioprotective effect (directly via bradykinin action, indirectly via endothelium-derived relaxing factor action); (5) LMW-kininogen inhibits the aggregation of thrombocytes; (6) LMW-kininogen is in contrast to HMW-kininogen not involved in blood clotting.
  • Tissue specificity
    Secreted in plasma. T-kinin is detected in malignant ovarian, colon and breast carcinomas, but not in benign tumors.
  • Involvement in disease
    Defects in KNG1 are the cause of high molecular weight kininogen deficiency (HMWK deficiency) [MIM:228960]. HMWK deficiency is an autosomal recessive coagulation defect. Patients with HWMK deficiency do not have a hemorrhagic tendency, but they exhibit abnormal surface-mediated activation of fibrinolysis.
  • Sequence similarities
    Contains 3 cystatin domains.
  • Post-translational
    modifications
    Bradykinin is released from kininogen by plasma kallikrein.
    Hydroxylation of Pro-383 occurs prior to the release of bradykinin.
    Phosphorylation sites are present in the extracelllular medium.
    N- and O-glycosylated. O-glycosylated with core 1 or possibly core 8 glycans.
  • Cellular localization
    Secreted > extracellular space.
  • Information by UniProt
  • Database links
  • Alternative names
    • Alpha 2 thiol proteinase inhibitor antibody
    • Alpha-2-thiol proteinase inhibitor antibody
    • BDK antibody
    • BK antibody
    • Bradykinin antibody
    • Fitzgerald factor antibody
    • High molecular weight kininogen antibody
    • HMWK antibody
    • Ile-Ser-Bradykinin antibody
    • Kallidin I antibody
    • Kallidin II antibody
    • Kininogen 1 antibody
    • KNG antibody
    • KNG1 antibody
    • KNG1_HUMAN antibody
    • Low molecular weight growth-promoting factor antibody
    • Williams-Fitzgerald-Flaujeac factor antibody
    see all

References

This product has been referenced in:
  • Hansen CB  et al. The Levels of the Lectin Pathway Serine Protease MASP-1 and Its Complex Formation with C1 Inhibitor Are Linked to the Severity of Hereditary Angioedema. J Immunol 195:3596-604 (2015). Read more (PubMed: 26371246) »

See 1 Publication for this product

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab79654.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up